0

536565

NOVELIX

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

NOVELIX PHARMACEUTICALS LIMITE Share Price Today

Investment Returns

Over 1 Month 49.93% Over 3 Months 46.87% Over 6 Months 32.66% Over 1 Year 172.11%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

NOVELIX PHARMACEUTICALS LIMITE fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 181.20
  • P/E Ratio (TTM) 74.59
  • Beta 0.62
  • Book Value / share 21.80
  • Return on equity 0.56%
  • EPS (TTM) 1.07
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 0.91
info icon alternate text

NOVELIX PHARMACEUTICALS LIMITE Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 25.19
Operating Expense 23.96
Net Profit 0.91
Net Profit Margin (%) 3.61
Earnings Per Share (EPS) 0.43
EBITDA 1.28
Effective Tax Rate (%) 26.01
Particulars DEC 2025 (Values in Cr)
Revenue 48.40
Operating Expense 47.12
Net Profit 1.00
Net Profit Margin (%) 2.06
Earnings Per Share (EPS) 0.58
EBITDA 1.31
Effective Tax Rate (%) 21.87
Particulars SEP 2025 (Values in Cr)
Revenue 36.36
Operating Expense 35.67
Net Profit 0.53
Net Profit Margin (%) 1.45
Earnings Per Share (EPS) 0.37
EBITDA 0.73
Effective Tax Rate (%) 26.38
Particulars JUN 2025 (Values in Cr)
Revenue 22.35
Operating Expense 22.18
Net Profit 0.11
Net Profit Margin (%) 0.49
Earnings Per Share (EPS) 0.09
EBITDA 0.18
Effective Tax Rate (%) 35.29
Particulars MAR 2025 (Values in Cr)
Revenue 20.86
Operating Expense 20.65
Net Profit 0.18
Net Profit Margin (%) 0.86
Earnings Per Share (EPS) 0.18
EBITDA 0.22
Effective Tax Rate (%) 14.28
Particulars MAR 2026 (Values in Cr)
Revenue 132.31
Operating Expense 128.93
Net Profit 2.56
Net Profit Margin (%) 1.93
Earnings Per Share (EPS) 1.21
EBITDA 3.50
Effective Tax Rate (%) 25.00
Particulars MAR 2025 (Values in Cr)
Revenue 30.72
Operating Expense 30.61
Net Profit 0.08
Net Profit Margin (%) 0.26
Earnings Per Share (EPS) 0.08
EBITDA 0.16
Effective Tax Rate (%) 33.33
Particulars MAR 2024 (Values in Cr)
Revenue 4.22
Operating Expense 4.51
Net Profit 0.01
Net Profit Margin (%) 0.23
Earnings Per Share (EPS) 0.01
EBITDA 0.06
Effective Tax Rate (%) 50.00
Particulars MAR 2023 (Values in Cr)
Revenue 1.40
Operating Expense 1.98
Net Profit -0.06
Net Profit Margin (%) -4.28
Earnings Per Share (EPS) -0.07
EBITDA 0.00
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 0.84
Operating Expense 2.96
Net Profit -1.56
Net Profit Margin (%) -185.71
Earnings Per Share (EPS) -1.93
EBITDA -1.50
Effective Tax Rate (%) 0.63
Particulars MAR 2022 (Values in Cr)
Book Value / Share 9.14
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.01
EBITDA Margin -20.22
Particulars MAR 2021 (Values in Cr)
Book Value / Share 8.47
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.04
EBITDA Margin -36.18
Particulars MAR 2020 (Values in Cr)
Book Value / Share 13.09
ROE % -2.42
ROCE % -0.86
Total Debt to Total Equity 0.08
EBITDA Margin 0.92
Particulars MAR 2019 (Values in Cr)
Book Value / Share 13.48
ROE % -1.54
ROCE % -0.93
Total Debt to Total Equity 0.09
EBITDA Margin 1.00
Particulars MAR 2018 (Values in Cr)
Book Value / Share 13.79
ROE % -2.99
ROCE % -0.07
Total Debt to Total Equity 0.09
EBITDA Margin 2.16
Particulars MAR 2025 (Values in Cr)
Book Value / Share 17.63
ROE % 0.56
ROCE % 0.84
Total Debt to Total Equity 0.00
EBITDA Margin 0.52
Particulars MAR 2024 (Values in Cr)
Book Value / Share 9.08
ROE % 0.12
ROCE % 0.24
Total Debt to Total Equity 0.00
EBITDA Margin 1.42
Particulars MAR 2023 (Values in Cr)
Book Value / Share 8.88
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 8.94
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -107.19
Particulars MAR 2021 (Values in Cr)
Book Value / Share 10.87
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -243.51
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.88
Total Assets 8.73
Total Liabilities 8.73
Total Equity 7.67
Share Outstanding 0
Price to Book Ratio 0.99
Return on Assets (%) -20.60
Return on Capital (%) -23.05
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2.07
Total Assets 9.57
Total Liabilities 9.57
Total Equity 7.36
Share Outstanding 0
Price to Book Ratio 0.62
Return on Assets (%) -39.06
Return on Capital (%) -50.77
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.11
Total Assets 13.72
Total Liabilities 13.72
Total Equity 11.12
Share Outstanding 0
Price to Book Ratio 0.13
Return on Assets (%) -2.06
Return on Capital (%) -2.38
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 0.19
Total Assets 13.34
Total Liabilities 13.34
Total Equity 11.42
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) -1.81
Return on Capital (%) -1.96
Particulars MAR 2018 (Values in Cr)
Cash & Short Term Investments 0.35
Total Assets 13.57
Total Liabilities 13.57
Total Equity 11.57
Share Outstanding 0
Price to Book Ratio 0.52
Return on Assets (%) -2.56
Return on Capital (%) -2.77
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.67
Total Assets 27.20
Total Liabilities 27.20
Total Equity 17.53
Share Outstanding 0
Price to Book Ratio 1.51
Return on Assets (%) 0.31
Return on Capital (%) 0.48
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.11
Total Assets 7.36
Total Liabilities 7.36
Total Equity 7.35
Share Outstanding 0
Price to Book Ratio 1.89
Return on Assets (%) 0.14
Return on Capital (%) 0.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.27
Total Assets 7.25
Total Liabilities 7.25
Total Equity 7.19
Share Outstanding 0
Price to Book Ratio 1.01
Return on Assets (%) -0.82
Return on Capital (%) -0.83
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.60
Total Assets 7.25
Total Liabilities 7.25
Total Equity 7.24
Share Outstanding 0
Price to Book Ratio 0.99
Return on Assets (%) -21.51
Return on Capital (%) -21.54
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.73
Total Assets 8.76
Total Liabilities 8.76
Total Equity 8.80
Share Outstanding 0
Price to Book Ratio 0.62
Return on Assets (%) -37.28
Return on Capital (%) -37.13
Particulars MAR 2022 (Values in Cr)
Net Income -2.12
Cash from Operations 1.10
Cash from Investing -0.75
Cash from Financing 0.00
Net change in Cash 0.82
Free Cash Flow 2.90
Particulars MAR 2021 (Values in Cr)
Net Income -3.72
Cash from Operations 1.62
Cash from Investing 0.13
Cash from Financing -0.76
Net change in Cash 0.96
Free Cash Flow 1.64
Particulars MAR 2020 (Values in Cr)
Net Income -0.21
Cash from Operations 0.73
Cash from Investing 0.45
Cash from Financing -0.16
Net change in Cash 0.91
Free Cash Flow 0.83
Particulars MAR 2019 (Values in Cr)
Net Income -0.12
Cash from Operations -0.52
Cash from Investing 0.42
Cash from Financing -0.04
Net change in Cash -0.15
Free Cash Flow -0.38
Particulars MAR 2018 (Values in Cr)
Net Income -0.30
Cash from Operations 0.49
Cash from Investing -0.63
Cash from Financing 0.02
Net change in Cash -0.24
Free Cash Flow 0.86
Particulars MAR 2025 (Values in Cr)
Net Income 0.12
Cash from Operations -13.68
Cash from Investing 2.93
Cash from Financing 11.31
Net change in Cash 0.56
Free Cash Flow -13.57
Particulars MAR 2024 (Values in Cr)
Net Income 0.02
Cash from Operations -0.34
Cash from Investing 0.18
Cash from Financing 0.00
Net change in Cash -0.15
Free Cash Flow -0.34
Particulars MAR 2023 (Values in Cr)
Net Income -0.05
Cash from Operations -2.40
Cash from Investing 0.07
Cash from Financing 0.00
Net change in Cash -2.33
Free Cash Flow -2.40
Particulars MAR 2022 (Values in Cr)
Net Income -1.56
Cash from Operations 0.59
Cash from Investing 0.27
Cash from Financing 0.00
Net change in Cash 0.86
Free Cash Flow 2.45
Particulars MAR 2021 (Values in Cr)
Net Income -3.27
Cash from Operations 0.58
Cash from Investing 0.20
Cash from Financing 0.00
Net change in Cash 0.78
Free Cash Flow 0.88
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 32.03 13.24 1.55 245.46 23.12 38.85
BLISS GVS PHARMA LTD. 481.70 39.10 4.28 5108.73 118.35 486.15
CIPLA LTD 1355.80 28.77 3.18 109527.67 1165.55 1672.20
FERMENTA BIOTECH LTD. 318.45 14.05 2.30 937.23 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 32.03 22.40 4.12 245.46 23.12 38.85
AMRUTANJAN HEALTH CARE LTD. 544.75 24.42 4.25 1574.91 490.00 789.95
ASTRAZENECA PHARMA IND LT 8514.50 111.20 24.38 21286.25 7630.00 10033.55
BLISS GVS PHARMA LTD. 481.70 51.96 4.42 5108.73 118.35 486.15

NOVELIX PHARMACEUTICALS LIMITE shareholding pattern

Holding
49.43%
50.56%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

NOVELIX PHARMACEUTICALS LIMITE Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
75.82 -4.99 redarrow
red-green-graph indicator
5 Bearish
11 Bullish
  • 5 Days 82.00
  • 26 Days 68.30
  • 10 Days 77.90
  • 50 Days 63.20
  • 12 Days 76.20
  • 100 Days 59.40
  • 20 Days 70.90
  • 200 Days 53.40
81.48 PIVOT
First Support 78.13 First Resistance 83.15 Second Support 76.46 Second Resistance 86.50 Third Support 73.11 Third Resistance 88.17
RSI 67.45 ADX 38.03 MACD 7.83 Williams % R -29.73 Commodity Channel Index (CCI) 82.35
Date 2026-06-18 Week 22040.00 Same Day 8109.00 Month 14484.00
1 Year 0.62 3 Year 0.35
Over 1 Month
49.93% down
Over 1 Year
172.11% down
Over 3 Months
46.87% down
Over 3 Years
106.22% down
Over 6 Months
32.66% down
Over 5 Years
54.62% down

NOVELIX PHARMACEUTICALS LIMITE Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
16 Aug 2012 0.3 Final 21 Aug 2012 Equity shares
22 Sep 2011 0.3 Final 25 Sep 2011 Equity shares
23 Aug 2010 0.03 Final 25 Aug 2010 Equity shares
01 Sep 2009 0.3 Final 03 Sep 2009 Equity shares
Ex-Date Old FV NEW FV Record Date
04 Oct 2010 1.0 10.0 05 Oct 2010
15 Oct 2009 10.0 1.0 16 Oct 2009

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Novelix Pharmaceuticals Ltd?

Answer Field

Novelix Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 75.82 as on Jun 19 2026 03:21 PM.

What is the Market Cap of Novelix Pharmaceuticals Ltd Share?

Answer Field

The market cap of Novelix Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 181.20 as on Jun 19 2026 03:21 PM.

What is the 52 Week High and Low of Novelix Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Novelix Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 92.00 and ₹ 29.33.

What is 1 year return for Novelix Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 172.11%.

What is the P/E Ratio of Novelix Pharmaceuticals Ltd Share?

Answer Field

As on Jun 19 2026 03:21 PM the price-to-earnings (PE) ratio for Novelix Pharmaceuticals Ltd share is 74.59.

What is the PB ratio of Novelix Pharmaceuticals Ltd Share?

Answer Field

As on Jun 19 2026 03:21 PM, the price-to-book (PB) ratio for Novelix Pharmaceuticals Ltd share is 21.80.

How to Buy Novelix Pharmaceuticals Ltd Share?

Answer Field

You can trade in Novelix Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Novelix Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Novelix Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Novelix Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image
Get Free Demat Account*
+91
close-img
Authorise with OTP
Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|